Perrigo announced that it has filed with the FDA an Abbreviated New Drug Application (ANDA) for Azelastine HCl nasal spray (0.15%), a generic of Astepro Nasal Spray. Perrigo has notified Meda, the manufacturer of Astepro.

Azelastine HCl nasal spray is indicated for the treatment of seasonal and perennial allergic rhinitis in patients ≥12 years old.

For more information, call (866) 634-9120 or visit www.perrigo.com.